The concept of MolecularMD grew out of discussions with Oregon Health Science University (OHSU) investigators, where the... Read More >   Exclusive Rights to Patented IP Related to Detection of Resistant BCR-ABL Mutations PORTLAND, Ore., May 27, 2008-- MolecularMD Corp, a developer and provider of cancer-based molecular diagnostics, announced today that it has entered into a license agreement with the Oregon Health & Science University to obtain exclusive commercial... Read Full Article OHSU To Offer Personalized Cancer Diagnostics In New Biotechnology Company PORTLAND, OR, May 16, 2007 Oregon Health & Science University has signed an agreement with MolecularMD, a private, molecular diagnostics company founded by scientific investigators including Brian Druker, M.D. The agreement gives OHSU an ownership... Read Full Article MolecularMD Joins CML Alliance to Provide Standardized RT-PCR BCR-ABL Patient Monitoring Diagnostics PORTLAND, OR., August 6, 2007 -- MolecularMD, a developer and provider of cancer-based molecular diagnostics, today announced its participation as a preferred provider of Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) patient... Read Full Article ChemGenex Teams with MolecularMD MELBOURNE, Australia, and MENLO PARK, California U.S.A., June 26, 2006 ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) today announced an alliance with MolecularMD, Inc., a leading provider of molecular diagnostic services, including drug... Read Full Article MolecularMD Enters into Agreement with Breakthrough Therapeutics to Support Phase II Clinical Trial Portland, Oregon August 15, 2006 MolecularMD, a molecular oncodiagnostics company, has recently entered into an agreement with Breakthrough Therapeutics, a private oncology company based in Greenwich, CT, to monitor residual disease levels in patients... Read Full Article MolecularMD to attend the ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer 2008 October 30, 2008    MolecularMD will attend the ASCO-NCI-EORTC Meeting on Molecular Markers in Cancer from October 30 through November 1, 2008 at the Westin Diplomat Resort and Spa in Hollywood Florida. Please make sure to stop by our booth and say hello! MolecularMD to attend the 50th ASH Annual Meeting and Exposition December 6, 2008    MolecukarMD will attend the 50th ASH Annual Meeting and Exposition December 6th - 8th, 2008 at the Moscone Convention Center in San Francisco. Please be sure to come by our booth and say hello!